Epithelial cancers can arise from BM-derived cells (BMCs) in animal models. We studied whether the same phenomenon can occur in humans. Biopsy specimens from carcinomas and healthy adjacent tissues were obtained from three women who had undergone allogeneic BMT from an HLA-matched brother. Complete donor hematopoietic chimerism was verified by cytogenetic analysis, RFLP analysis or by reverse transcription-PCR analysis. Biopsies were studied for the presence of the Y chromosome derived from BM-derived cells by combined FISH and immunohistochemical staining. In our studies, we showed that human epithelial neoplastic and adjacent nonneoplastic tissues incorporate the Y chromosome at low and comparable rates. The lack of enrichment in malignancies argues against the possibility that BMderived cells represent a direct source of carcinomas, and we suggest that these cells randomly contribute to neoplastic and non-neoplastic epithelial cells. On the basis of the absence of a fusion karyotype, we favor a model in which the differentiation of BM-derived cells is largely determined by the microenvironment encountered.
Introduction
BM-derived cells (BMCs) have been shown to differentiate into hematopoietic and non-hematopoietic lines, [1] [2] [3] [4] and to contribute, in an animal model, to the development of gastric dysplasia and cancer in response to chronic inflammation. 5 Whether BMCs participate in the formation of solid neoplasms in humans remains unclear. Previous studies yielded conflicting results, [6] [7] [8] [9] probably because of different technical approaches and the use of inadequately rigorous methods. Therefore, carcinomas and adjacent non-neoplastic tissues from female recipients of HLAmatched, sex-mismatched BM cells were analyzed for the presence of genetic material from the male donor by combining FISH with immunofluorescence labeling, and by the examination of the specimens with confocal microscopy.
Materials and methods

Patients' characteristics
We identified three women who had undergone allogeneic BMT for the treatment of hematologic diseases (Table 1) and developed a carcinoma 12-21 years later. The recipients developed a mucoepidermoid carcinoma of the parotid gland, an invasive ductal carcinoma of the breast and both a papillary thyroid carcinoma and a carcinoma in situ of the cervix, respectively.
Induction protocols for BMT included myeloablative chemotherapy alone or combined with radiotherapy. Each allogeneic graft was derived from an HLA-matched brother.
Complete donor hematopoietic chimerism for the whole period between the transplant and the time of carcinoma diagnosis was demonstrated in all three female recipients by cytogenetic analysis, RFLP analysis or by reverse transcription-RT-PCR analysis on peripheral blood cells and BM cell aspirates ( Table 1) .
The examination of the specimens and the clinical status of the patients at the time of surgical removal of the tumors did not suggest a GVHD in the organs studied. The study protocol was approved by the local ethics committee.
Tissue specimens
Resection of the carcinomas in the three BMT recipients was performed for therapeutic purposes, and formalinfixed, paraffin-embedded tissues were available for further analysis. Serial sections of 4-mm thickness were obtained from representative tissue blocks of each carcinoma and surrounding non-neoplastic tissue. Sections were either stained with hematoxylin and eosin, analyzed for cytokeratins and the Y chromosome, or for the X and Y chromosomes.
As a control, two mucoepidermoid carcinomas of the parotid gland, two papillary thyroid carcinomas and two mammary invasive ductal carcinomas of women, who had not undergone BMT, and two papillary thyroid carcinomas, one mucoepidermoid carcinoma of the parotid gland, two invasive ductal carcinomas of the breast and one normal lymph node in male patients were included in the study.
FISH for the X and Y chromosomes Sections were deparaffinized in xylol, dehydrated in 100% ethanol, incubated in 0.2 mol/l HCl solution at room temperature for 20 min, immersed in pre-treatment solution (Vysis, Downers Grove, IL, USA) for 10 min at 80 1C, and digested with Protease I (Vysis) (250 mg in 2 Â saline sodium citrate (SSC), pH 7.0) for 15-20 min at 37 1C. After dehydration in ethanol series, target sections, CEP Y Spectrum Orange and CEP X Spectrum Green probes (Vysis), which cover classical satellite III and alpha satellite sequences on the sex chromosomes, respectively, were co-denaturated at 80 1C for 6 min and allowed to hybridize overnight at 42 1C. Post-hybridization stringency washes were performed in 2 Â SSC/0.3 NP40 at 72 1C for 5 min and in 2 Â SSC for 2 min at room temperature. Finally, after rinsing twice with 1 Â PBS at room temperature, 10 ml 4 0 ,6-diamidino-2-phenylindole (DAPI II; Vysis) was applied to the samples for chromatin counterstaining.
Combined FISH and immunohistochemistry
For combined FISH and immunohistochemical staining, sections were allowed to hybridize with the CEP Y Spectrum Orange probe and washed with SSC as above mentioned. Subsequently, slides were rinsed in 1 Â PBS for 5 min at room temperature, and incubated overnight at 4 1C with monoclonal mouse anti-human cytokeratin antibodies (anti-keratin polypeptide of 45, 46 and 56.5 kDa (clone MNF116; Medite, Burgdorf, Germany)) at a dilution of 1:50 in 1 Â PBS. Slides were then rinsed three times with 1 Â PBS for 5 min at room temperature. The antigenantibody reaction was visualized after incubation for 30 min at 37 1C with secondary fluorescent polyclonal goat anti-mouse antibodies (Alexa Fluor 488; Invitrogen, Carlsbad, CA, USA) at a dilution of 1:200 in 1 Â PBS. Finally, after rinsing twice with 1 Â PBS at room temperature, 10 ml DAPI II (Vysis) was applied to the samples for chromatin counterstaining. Omission of the primary antibody and incubation with different antibodies of the same isotype were performed in control stainings.
Tissue analysis
Sections were evaluated with a Leica Sp1 scanning confocal microscope. Positive staining for epithelial-specific antigens combined with cellular and nuclear morphology characteristic for the various epithelia was a prerequisite for cell classification. Small round leukocyte-like cells and cells not expressing epithelial-specific antigens and damaged nuclei were not evaluated. To ensure representative sampling, 300-400 epithelial cells in at least six separate areas of each tumor and surrounding non-neoplastic tissue selected for well-preserved cellular and nuclear morphology were considered. 
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Statistical analysis
The percentage of cytokeratin-expressing cells carrying the Y chromosome between neoplastic and non-neoplastic tissues was compared by a two-tailed Student's t-test allowing for unequal or equal variances. This process was repeated separately for data from all patient samples. All calculations were carried out with the SAS System V8.
Results
To determine whether BM-derived cells can contribute to solid tumors and adjacent non-neoplastic tissues, we analyzed specimens by combined immunohistochemistry for cytokeratins and FISH for the Y chromosome. We identified three women who developed a mucoepidermoid carcinoma of the parotid gland, an invasive ductal carcinoma of the breast and both a papillary thyroid carcinoma and a carcinoma in situ of the cervix, respectively, after a BMT.
Within the tumors the percentage of cytokeratin-expressing cells with donor-derived genetic material as detected by FISH (Figures 1, 2 and 3 ) ranged from 0.8 ± 0.1% in invasive ductal carcinoma of the breast to 2.0±4% in mucoepidermoid carcinoma of the parotid gland (Table 2 ). In the surrounding non-neoplastic tissue of the same specimens, the percentages ranged from 1.5±2% in the breast to 2.1 ± 1% in the cervix and were not significantly different from the percentages found in the corresponding neoplastic tissue (P-values ranging from 0.95 to 0.97) ( Table 2) .
Importantly, no Y-positive cells were detected in tumor specimens or surrounding tissue from women who did not receive BMT (Table 2) , demonstrating the high specificity of our technique.
The sensitivity of our FISH technique was, however, limited to 71.3-81.5% as shown by the presence of the Y chromosome in neoplastic and non-neoplastic epithelial cells obtained from the male patients of the control group (Table 2) , owing to truncation of the nuclei during sectioning and incomplete hybridization. 0 ,6-diamidino-2-phenylindole; H&E, hematoxylin and eosin.
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To address whether neoplastic and non-neoplastic epithelial cells carrying BM-derived genetic material derived from a stable fusion, we performed karyotype analysis by XY FISH hybridization of the neoplastic and surrounding non-neoplastic tissues on adjacent sections and detected only XY, XX, X0 and Y0 combinations, that is fusion karyotype was not observed (Figure 4) .
Discussion
In the last few years, BMCs have been reported to play an important role in tumor development and progression, as they are involved in the vascularization and growth of specific primary solid tumors, 10 and in regulating the development of metastases. 11 In mice, a relationship has been shown between tissue damage caused by chronic bacterial infection with Helicobacter and repopulation of gastric mucosa by BMCs and the subsequent development of gastric dysplasia and carcinoma. 5 Even though normal tissue chimerism after BMCs transplantation is a real phenomenon, 12,13 the significance of BMCs in human nonhematologic malignancies has been contradictory, probably reflecting the use of different technologies with unsatisfactory stringency to clarify this issue. [6] [7] [8] [9] Tissue injury is reported to enhance the chances of BMCs contributing to non-hematopoietic tissues 2,4,14 by creating a favorable environment for the crossing of lineage barriers. As the neoplastic microenvironment is characterized by apoptosis or necrosis, and proliferation, 1, 3 we might expect higher rates of donor-derived cells in carcinomas compared with the normal counterparts. To address this issue, we screened paraffin-embedded specimens of four different solid epithelial tumors and surrounding non-neoplastic tissues arising in three female recipients 12-21 years after HLA-matched and sex-mismatched BMT for the presence of chimerism.
We showed the presence of the donor-derived genetic material in a fraction of neoplastic cells of all carcinomas and in the adjacent non-neoplastic epithelium, however, without significant differences. Our technique demonstrated high specificity, as no Y-positive cells were detected in tissues from women who did not receive BMT, whereas its sensitivity was limited as shown by a lower than expected rate of the Y chromosome in neoplastic and nonneoplastic epithelial cells obtained from the male patients of the control group. This was probably due to truncation of the nuclei during sectioning and incomplete hybridization, and as a consequence the percentages found for the Y chromosome in carcinomas of our BMT patients are slightly underestimated.
The lack of enrichment in malignancies argues against the possibility that BM-derived cells represent a direct source of carcinomas. Therefore, we suggest that these cells randomly contribute to neoplastic and non-neoplastic epithelial cells. Several mechanisms may be invoked to explain BMC plasticity, which can be categorized as either direct/indirect differentiation (transdifferentiation) or cell fusion. 3, 4 Cells derived by cell fusion would first include tetraploid nuclei and diploid nuclei would eventually arise after chromosome loss and/or reduction division. 15 On the basis of the complete absence of a fusion karyotype, fusion events seem to be unlikely. Therefore, even if our results are not conclusive, we favor a model in which the differentiation of BM-derived cells is largely determined by the microenvironment encountered.
An alternative source for the Y chromosome could be represented by pregnancy-associated progenitor cells, which have been demonstrated to be transferred into the maternal circulation during pregnancy and persist in maternal organs without any apparent graft-versus-host reaction, even in case of fetal loss. This phenomenon has been called fetal cell microchimerism. 16 Recently, it has been hypothesized that pregnancy-associated progenitor cells persist in a maternal stem cell niche and, in the case of tissue injury, home to the damaged organ and differentiate as part of the maternal response. In our study, a fetal source in BMT patients is, however, unlikely, as they did not report any pregnancy and in the control female group no Y chromosome was detected. Our results rather underline the possible similarities existing between fetal cell chimerism and incorporation of donor-derived material in the recipient cells.
On the basis of the present findings, BMCs do not seem to have a malignant potential. Importantly, the fact that solid tumors contain genetic material from cells of BM origin could have implications for gene therapy protocols, even though its potential may be considerably hampered by low engraftment rates and, possibly, by gene silencing or selection events. 
